Refine your search

Search Results within category "Digestive Systems & Liver Disease"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Digestive Systems & Liver Disease"


13 Study Matches

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn's Disease

This study is for patients with moderate to severely active Crohn's disease to measure how effective and safe an experimental medication is in treating this condition.
Laurie Peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03599622
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
moderate to severe crohn's disease, 3 months
failed prior treatment
Exclusion Criteria:
severe or fulminant colitis requiring surgery
presence of stoma, gastric pouch
prior bowel resection, 6 months
bleeding disorders
cancer < 5 years
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Preventing de novo portal vein thrombosis with Antithrombin-III in patients with cirrhosis: A randomized, double-blinded, placebo - controlled trial (PiVoT-AC Trial)

Portal vein thrombosis (PVT) is blockage or narrowing of the portal vein (the blood vessel that brings blood to the liver from the intestines) by a blood clot. It is a common complication in patients with cirrhosis. There is an understanding that patients with cirrhosis are at higher risk for clotting events. This study will examine the use of antithrombin III (a protein found in the body) as a potential drug that may prevent blood clotting in patients with cirrhosis.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04055389
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults age ≥18 or ≤75 years
Cirrhosis diagnosis
Exclusion Criteria:
pregnancy
active Hepatitis C infection
HIV infection
recent major surgery within six weeks
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

this study is looking for patients with compensated cirrhosis as the result of non-alcoholic steatohepatitis (NASH). ]). NASH is the result of too much fat within the liver, resulting in injury and death to individual liver cells; the presence of injury like this is followed by progressive formation (laying down) of liver fibrosis (scar tissue); the result of this is increased liver stiffness. As more and more fibrosis is formed and laid down in the liver, the outcome is cirrhosis. Compensated cirrhosis means the liver has become very scarred but can still perform many important bodily functions. This research is being done to find out how safe and effective the investigational drug (also called a study drug) obeticholic acid (also known as OCA) may be in improving compensated cirrhosis caused by NASH (non-alcoholic steatohepatitis). Currently, there are no therapies approved for the treatment of NASH. OCA (the brand name is Ocaliva) has been approved in several regions in North Americacountries (including the United States,and Canada) and Europe) for the treatment of another form of chronic liver disease called Primary Biliary Cholangitis (PBC).
Laurie Peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03439254
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
NASH with cirrhosis
willing to use contraception
Exclusion Criteria:
hepatic decompensation
history of liver transplant
significant cardiovascular disease
alcohol abuse
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis

This study is for patients with Primary Sclerosing Cholangitis which is a chronic disease which causes scarring of the bile ducts. This can lead to damage of the liver over time. The purpose of this study is to see if an experimental medication slows the scarring process.
Laurie Peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03890120
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-70 years old
Diagnosis of Primary Sclerosing Cholangitisi
Exclusion Criteria:
Liver cirrhosis
Received a liver transplant
Liver cancer
HIV or Hepatitis B or C diagnosis
Alcohol use exceeding limits
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet

This study is for patients with Celiac disease. We are studying whether an investigational drug will reduce symptoms associated with Celiac disease when taken while on a gluten free diet.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03569007
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
BMI between 16 and 45
Celiac diagnosis for at least 6 months
Follows a gluten free diet
Exclusion Criteria:
Open abdominal surgery in the last 6 months
Chronic GI disease other than celiac
Received antibiotics in past 4 weeks
Diagnosis of cancer in past 5 years
Uncontrolled Type 2 diabetes
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Perception of Eating Specific Food and Liquid Textures

The purpose of this qualitative/quality of life (QOL) research study is to learn more about people's thoughts and opinions regarding eating specific food and drinking specific liquid textures. We are interested in learning how people's food and drink preferences change with age.
Nicole Etter at oppal@psu.edu or 814-863-2021
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
40 years and older
Hearing proficiency enough to complete a semi-structured interview
English proficiency enough to complete a semi-structured interview
Exclusion Criteria:
History of dysphagia (swallowing disorders)
Currently on a modified dysphagia diet
Currently receiving treatment for dysphagia (swallowing problem)
Participant reports diagnosed dementia or related cognitive disorder
Participant reports any progressive neurologic diagnosis (e.g. Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), etc)
Food & Nutrition, Digestive Systems & Liver Disease, Diabetes & Hormones
  Email this study information to me
  Contact the study team

A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid

This is a phase 3 double-blind (DB), randomized, placebo-controlled study with an open-label long term extension (LTE) evaluating the efficacy and safety of Elafibranor 80 mg once daily versus placebo in patients with PBC and inadequate response or intolerance to ursodeoxycholic acid (UDCA). In the DB period, patients will be randomized in a 2:1 ratio to receive Elafibranor 80 mg or placebo, once daily. The DB period will last until the last completed week 52 (V6) or until a maximum of 104 weeks DB period, whichever happens first, to further collect safety and clinical outcomes data in a DB manner. After the DB period, all patients will receive Elafibranor 80 mg daily for up to 5 years during the LTE period.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04526665
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Males or females age of 18 to 75 years inclusive at first Screening Visit (SV)
Definite or probable PBC diagnosis
on UDCA for at least 12 months prior to screening or have history of being unable to tolerate UDCA
Exclusion Criteria:
History or presence of other concomitant liver disease
Clinically significant hepatic decompensation
Other clinically significant medical conditions that are not well controlled or for which medication needs are anticipated to change during the study
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Mobile Health Delivered Lifestyle Intervention Program in Patients with Nonalcoholic Steatohepatitis: A Proof of Concept Study

Subjects will be given access to the Noom Healthy Weight (HW) application for 16-weeks.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04872777
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults age >18 years
NASH diagnosis
possession of smart phone
Exclusion Criteria:
Active or recent participation in lifestyle intervention program
Active weight-loss supplement use
Cirrhosis
Inability to provide informed consent
Other chronic liver disease
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information

CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: A Prospective, Randomized, Double-blind, Multi-center Clinical Trial

This study seeks to verify the findings of the CHARM I pilot study by conducting a multi-center clinical trial. We hypothesize that: • Pancreatic cyst infusion with a specifically designed drug therapy cocktail following normal saline lavage will result in cyst destruction rates that do not significantly differ from those achieved by alcohol-based cyst treatment (ethanol lavage followed by infusion of the same chemotherapeutic cocktail). • The removal of alcohol from the procedure will decrease both serious and minor adverse event rates associated with pancreatic cyst treatment. • There may be molecular markers contained within the fluid of these cystic tumors which identify cysts that are favorable to or resistant to EUS-guided fine needle infusion using this drug combination. As such, we will test all treated cysts for 10 of the best known molecular markers for evaluation in post study analysis. We expect that administering a specifically designed chemotherapeutic cocktail without prior alcohol lavage will result in an equivalent rate of cyst resolution with fewer complications when compared to alcohol. The results of this study will provide important information about the most efficient and safest method for treating premalignant pancreatic cysts, an important step for treating these lesions with a minimally invasive technique and preventing their progression to cancer. Standard alternative treatment options for this patient group (if not taking part in this study) would be ongoing periodic radiographic monitoring with MR or CT imaging waiting for signs of cancer to develop or to consider surgical removal of the affected tissue.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03085004
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult subjects over the age of 18.
Patients with a previously-detected pancreatic cyst(s) 2-5 cm in diameter which are consistent with a mucinous type cyst as per ASGE guidelines including indeterminate type cysts.
Ability to give written informed consent.
Capable of safely undergoing endoscopy with deep sedation or general anesthesia.
Exclusion Criteria:
Lesions which are consistent with a benign cyst by clinical, cytological, chemical, and radiographic evaluation as per ASGE guidelines37 (i.e., consistent with a pseudocyst or serous cystadenoma).
Known or suspected pancreatic cancer or pathologic lymphadenopathy.
Cysts with the following high risk features: main pancreatic duct dilation of > 5mm,epithelial type mural nodules , pathologically thick wall/septation (> 2mm)..
Septated cysts with > 4 compartments.
Confirmed pancreatitis within the last 3 months.
Digestive Systems & Liver Disease, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

This study is for patients who have been diagnosed with or have signs and symptoms of moderately to severely active Crohn's disease (CD) which is a chronic inflammatory disorder of the bowels. People with CD often suffer from diarrhea, abdominal pain, rectal bleeding, weight loss, and fever. This study is being done to see whether an experimental medication that is not approved by the Food and Drug Administration, is safe and effective for the possible treatment of CD. To do this, a comparison will be made between people who receive active drug and people who receive placebo (a ‘dummy treatment’ that looks like the active drug but contains no active ingredient). The purpose of this study is to confirm preliminary results from a phase II study that suggests that the active drug may be safe and effective in treating patients with CD.
Laurie Peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03440372
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 18-75, inclusive
Diagnosis of Crohn's Disease for at least 3 months
Failed prior treatment
Exclusion Criteria:
Will need surgery in 3 months
Stricture or obstruction symptoms
Prior cancers
Drug or alcohol abuse within 1 year
Diagnosis of colitis
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn’s disease over a period of 24 weeks and a follow-up period up to 52 weeks. ADMIRE-CD II study.

This study is for patients with Crohn's disease which involves an investigational new drug to treat perianal fistulas in patients with Crohn’s disease (CD). The purpose of this study is to find out: 1) How well the study drug works at a single dose compared to a placebo; 2) how safe and tolerable the study drug is in patients with fistulizing CD.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03279081
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Crohn's Disease for at least 6 months
Presence of complex perianal fistulas
Clinically controlled, non active or mildly active CD during the last 6 months
Patients whose perianal fistulas were previously treated and have shown an inadequate response
Exclusion Criteria:
Any major surgery of the GI tract within past 6 months
Patients without prior specific treatment for perianal complex fistulas
Patients with diverting stomas
Patients with active, uncontrolled infection requiring IV antibiotics
Patients with allergies or hypersensitivity to penicillin or aminoglycosides, local anesthetics or MRI contrast
Infectious Diseases & Immune System, Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (NASH)

This Phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter international study will evaluate the effect of OCA on histological improvements in NASH, all-cause mortality, and liver-related clinical outcomes. Primary Objective Assessed at 18 Months • To evaluate the effect of OCA compared to placebo on histological improvement in NASH by assessing the following as co-primary endpoints using NASH CRN scoring criteria: − Improvement in fibrosis by at least 1 stage with no worsening of NASH defined as no increase in hepatocellular ballooning or lobular inflammation Page 33 of 261 Protocol 747-303 Version 4: 14 Apr 2016 Page 34 Confidential and Proprietary − Resolution of NASH as defined by overall histopathological interpretation with no worsening of fibrosis 6.2. Secondary Objectives Assessed at 18 Months • To evaluate the effect of OCA compared to placebo on histological improvement in NASH by assessing the following using NASH CRN scoring criteria: − Improvement of fibrosis and NASH as a composite endpoint and as defined by improvement in fibrosis by at least 1 stage and improvement in NAFLD activity score (NAS) by at least 2 points with at least 1 point improvement each for hepatocellular ballooning and lobular inflammation − Resolution of fibrosis − Improvement in NAS by at least 2 points with no worsening of fibrosis − Improvement in each key histological feature of NASH by at least 1 point (steatosis, lobular inflammation, and hepatocellular ballooning)
laurie peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02548351
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
NASH
fibrosis stage 2 or 3
stable body weight
Exclusion Criteria:
cirrhosis
prior cancer
heptocellular cancer
hiv, hcv, hbv
hba1c>9.5
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

NASH Fitness Intervention for Thrombosis (NASHFit) Trial

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. The most advanced forms of NAFLD are associated with increased liver-related mortality and lower overall survival. The current standard of care for NAFLD is lifestyle changes through diet and exercise. The human genome and regulation of gene expression is influenced by physical activity. NAFLD is a prothrombotic state with derangements in all three phases of hemostasis leading to clinically important clotting events. Exercise can improve coagulation in healthy persons. In this proposal, we seek to begin a line of work to answer the question “Can lifestyle changes effectively mitigate the increased risk of clotting in patients with NAFLD?” focusing initially on the at-risk population genetically susceptible to advanced disease.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03518294
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Nonalcoholic fatty liver disease (NAFLD)
Evidence of hepatic steatosis by imaging
Exclusion Criteria:
>90 minutes/week of at least moderate intensity exercise over the previous three months
Pregnancy
Active cardiac symptoms
Uncontrolled diabetes (changes in medication dosing over the previous three months or hemoglobin A1c >9%)
Blood Disorders, Digestive Systems & Liver Disease, Sports Medicine
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA